Regeneron teams up with Gary Nabel’s ModeX on multispecificsnews2025-10-29T14:22:25+00:00October 29th, 2025|Endpoints News|
Weight loss drugs could be cost-effective even at higher prices, ICER saysnews2025-10-29T12:21:07+00:00October 29th, 2025|Endpoints News|
GSK trims pipeline, bumps guidance in Emma Walmsley’s last earnings reportnews2025-10-29T11:34:00+00:00October 29th, 2025|Endpoints News|
Lilly keeps up legal fight against GLP-1 compounders news2025-10-28T19:40:58+00:00October 28th, 2025|Endpoints News|
FDA clears at-home use for Delix’s next neuroplastogen studynews2025-10-28T19:22:46+00:00October 28th, 2025|Endpoints News|
FDA’s biosimilars director says agency seeks to ‘streamline’ developmentnews2025-10-28T18:41:12+00:00October 28th, 2025|Endpoints News|
Eli Lilly, Nvidia say they’ll build pharma’s most powerful supercomputernews2025-10-28T18:30:18+00:00October 28th, 2025|Endpoints News|
More than a third of Lilly’s new Zepbound prescriptions are coming from DTCnews2025-10-28T16:28:14+00:00October 28th, 2025|Endpoints News|
BioMarin looks to divest hemophilia gene therapy Roctaviannews2025-10-28T15:29:37+00:00October 28th, 2025|Endpoints News|
UK government delays drug rebate scheme deadline for drugmakers news2025-10-28T14:02:16+00:00October 28th, 2025|Endpoints News|
